Hot Investor Mandate 1: Australia-Based Firm Invests in Clinical-Stage Drugs & Marketed Devices

25 Aug

A venture capital firm based in Sydney, Australia makes early-late stage investments into several industries with a focus on transformative technologies, including: Life Sciences, IT, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics, and food security. The firm has raised 2 funds to date and currently has A$ 200M in funds under management, and is investing with a primary focus on companies raising Series B rounds onwards, though will consider companies raising Series A. Depending on the stage, the firm can invest from A$ 4M up to A$ 20M per company. Most of the firm’s investments are in Australian-based companies but 20% of investments are for off-shore investments outside of Australia, as the firm has looked at technology in the USA, Israel, and Singapore. The firm is actively seeking 3-4 new investment opportunities within the next year.

In the Life Sciences, the firm seeks to invest in biotech, specialty pharma, medical technology/device, diagnostics, and healthcare IT. The firm looks at post-Ph I clinical-stage products that have a strong proof-of-concept at a minimum, and typically invests in products with well-progressed and well-defined regulatory and reimbursement pathways. If a medical device, the product should be approaching profitability with capital required to fuel growth and global expansion. The firm is only interested in indications with a significant global market, and will not look at biosimilars, generics, and indications and technology that require large rounds in their Ph III-study.

In Healthcare IT, the firm is interested in eHealth apps, self-management and CRM software technology. The firm is also interested in food and environmental biotech opportunities.

The firm requires board representation post-investments. The firm will actively help with hiring a full management team, senior management team, and board, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: